Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13325944 | 0.82 | POLB (0.33) | POLBCA12CA1CA2CA9 | |
| SCHEMBL1104601 | 0.80 | — | — | |
| SCHEMBL1104576 | 0.71 | ALDH1A1 (0.44) | TSHR | |
| SCHEMBL13992898 | 0.67 | CA9 (0.40) | POLBCA12CA1CA2CA9 | |
| SCHEMBL7146522 | 0.65 | ALDH1A1 (0.42) | POLBCA12CA1CA2CA9 | |
| SCHEMBL13311377 | 0.65 | — | — | |
| SCHEMBL20581903 | 0.65 | ALDH1A1 (0.42) | POLBCA12CA1CA2CA9 | |
| SCHEMBL21819708 | 0.65 | ALDH1A1 (0.42) | POLBCA12CA1CA2CA9 | |
| SCHEMBL7153104 | 0.65 | ALDH1A1 (0.42) | POLBCA12CA1CA2CA9 | |
| SCHEMBL16869447 | 0.65 | ALDH1A1 (0.42) | POLBCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541599-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153725-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7718810-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7576119-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | POLB 512/4885CA12 2383/4885CA1 2308/4885 |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | POLB 512/4885CA12 2383/4885CA1 2308/4885 |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | POLB 512/4885CA12 2383/4885CA1 2308/4885 |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | POLB 512/4885CA12 2383/4885CA1 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.